PlainRecalls
FDA Drug Moderate Class II Ongoing

Doxepin Hydrochloride Capsules, USP, 10 mg, 100 Capsules, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panela v 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-637-31

Reported: August 13, 2025 Initiated: July 25, 2025 #D-0566-2025

Product Description

Doxepin Hydrochloride Capsules, USP, 10 mg, 100 Capsules, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panela v 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-637-31

Reason for Recall

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Details

Units Affected
9,492 bottles
Distribution
Nationwide in the USA.
Location
Panchmahal, N/A

Frequently Asked Questions

What product was recalled?
Doxepin Hydrochloride Capsules, USP, 10 mg, 100 Capsules, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panela v 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-637-31. Recalled by Alembic Pharmaceuticals Limited. Units affected: 9,492 bottles.
Why was this product recalled?
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 13, 2025. Severity: Moderate. Recall number: D-0566-2025.